Literature DB >> 10047653

Venovenous modified ultrafiltration after cardiopulmonary bypass in children: a prospective randomized study.

H A Hennein1, U Kiziltepe, S Barst, K A Bocchieri, A Hossain, D R Call, D G Remick, J P Gold.   

Abstract

BACKGROUND: Cardiopulmonary bypass is associated with the production of both proinflammatory and anti-inflammatory cytokines, the balance of which leads to varying degrees of postoperative systemic inflammation. Arteriovenous modified ultrafiltration effectively reduces total body water and improves postoperative hemodynamic and homeostatic functions. Venovenous modified ultrafiltration is a modification of this technique, which has the potentially added advantage of eliminating the obligatory left-to-right shunt associated with arteriovenous modified ultrafiltration. We tested the hypothesis that venovenous modified ultrafiltration is a safe and effective method of achieving ultrafiltration in children after cardiopulmonary bypass.
METHODS: Thirty-eight pediatric patients were randomly assigned to undergo conventional, venovenous (n = 13), or no ultrafiltration venovenous (n = 13), and controls (n = 12). Perioperative, cardiopulmonary, and cytokine (tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, interleukin-8, and interleukin-10) data were collected for statistical analysis.
RESULTS: Compared with patients in the conventional ultrafiltration and control groups, patients undergoing venovenous modified ultrafiltration had the greatest volume of ultrafiltrate removed (46. 9 +/- 8.4 mL/kg vs 20.1 +/- 5.0 mL/kg and 0 mL/kg for conventional ultrafiltration and control groups, respectively; P =.0001), least increase in total body water (1.91% +/- 1.49% vs 3.90% +/- 1.86% and 8.24% +/- 3.41%; P =.05), greatest rise in hematocrit (39.7% +/- 1. 7% vs 33.8% +/- 2.1% and 29.6% +/- 2.3%; P =.006), and shortest length of hospital stay (4.41 +/- 0.28 days vs 6.69 +/- 1.47 days and 8.38 +/- 1.11 days; P =.03, P =.03).
CONCLUSIONS: Venovenous modified ultrafiltration is a safe and effective method of reducing the increase in total body water and duration of postoperative convalescence after cardiopulmonary bypass.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10047653

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  4 in total

1.  Use of the Quest Myocardial Protection System (MPS) for modified ultrafiltration during pediatric cardiac surgery.

Authors:  Cody C Trowbridge; Alfred H Stammers; Myra H Klayman; James D Murdock; Bianca R Yen; Christian L Gilbert
Journal:  J Extra Corpor Technol       Date:  2005-06

2.  Suppressive effect of phosphodiesterase type 4 inhibition on systemic inflammatory responses after cardiopulmonary bypass.

Authors:  Masaki Hamamoto; Michiharu Suga; Yuzo Takahashi; Yukio Sato; Shuji Inamori; Toshikatsu Yagihara; Takeshi Nakatani; Soichiro Kitamura
Journal:  J Artif Organs       Date:  2006       Impact factor: 1.731

3.  Autologous priming technique to reduce blood transfusion in pediatric cardiopulmonary bypass.

Authors:  Jacob Ostrowsky; Mark Henderson; Hani Hennein
Journal:  J Extra Corpor Technol       Date:  2006-06

4.  Fentanyl plasma levels after modified ultrafiltration in infant heart surgery.

Authors:  Andreas H Taenzer; Robert Groom; Reed D Quinn
Journal:  J Extra Corpor Technol       Date:  2005-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.